ARWR
Price
$13.24
Change
-$0.10 (-0.75%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
1.83B
13 days until earnings call
BCRX
Price
$8.39
Change
+$0.18 (+2.19%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
1.72B
6 days until earnings call
Ad is loading...

ARWR vs BCRX

Header iconARWR vs BCRX Comparison
Open Charts ARWR vs BCRXBanner chart's image
Arrowhead Pharmaceuticals
Price$13.24
Change-$0.10 (-0.75%)
Volume$19.81K
Capitalization1.83B
BioCryst Pharmaceuticals
Price$8.39
Change+$0.18 (+2.19%)
Volume$25.81K
Capitalization1.72B
ARWR vs BCRX Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. BCRX commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and BCRX is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (ARWR: $13.34 vs. BCRX: $8.22)
Brand notoriety: ARWR and BCRX are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 58% vs. BCRX: 89%
Market capitalization -- ARWR: $1.83B vs. BCRX: $1.72B
ARWR [@Biotechnology] is valued at $1.83B. BCRX’s [@Biotechnology] market capitalization is $1.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileBCRX’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • BCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, BCRX is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 5 TA indicator(s) are bullish while BCRX’s TA Score has 6 bullish TA indicator(s).

  • ARWR’s TA Score: 5 bullish, 3 bearish.
  • BCRX’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а +18.68% price change this week, while BCRX (@Biotechnology) price change was +11.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.20%. For the same industry, the average monthly price growth was -4.19%, and the average quarterly price growth was -12.04%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 11, 2025.

BCRX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($1.83B) has a higher market cap than BCRX($1.72B). BCRX YTD gains are higher at: 9.309 vs. ARWR (-29.043). BCRX has higher annual earnings (EBITDA): 12.8M vs. ARWR (-580.69M). ARWR has more cash in the bank: 553M vs. BCRX (321M). ARWR has less debt than BCRX: ARWR (525M) vs BCRX (809M). BCRX has higher revenues than ARWR: BCRX (451M) vs ARWR (2.5M).
ARWRBCRXARWR / BCRX
Capitalization1.83B1.72B107%
EBITDA-580.69M12.8M-4,537%
Gain YTD-29.0439.309-312%
P/E RatioN/AN/A-
Revenue2.5M451M1%
Total Cash553M321M172%
Total Debt525M809M65%
FUNDAMENTALS RATINGS
ARWR vs BCRX: Fundamental Ratings
ARWR
BCRX
OUTLOOK RATING
1..100
1024
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
31
Undervalued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8942
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for ARWR (96). This means that BCRX’s stock grew somewhat faster than ARWR’s over the last 12 months.

BCRX's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for ARWR (100). This means that BCRX’s stock grew somewhat faster than ARWR’s over the last 12 months.

ARWR's SMR Rating (99) in the Biotechnology industry is in the same range as BCRX (100). This means that ARWR’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for ARWR (89). This means that BCRX’s stock grew somewhat faster than ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for BCRX (100). This means that ARWR’s stock grew significantly faster than BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRBCRX
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
83%
Bearish Trend 18 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCLRX14.22N/A
N/A
BlackRock Advantage Large Cap Core Inv C
SMEAX13.14N/A
N/A
Invesco Small Cap Equity A
PMAQX43.30N/A
N/A
Principal MidCap R6
TAAGX10.50N/A
N/A
Timothy Plan Small/Mid Cap Growth Cl A
TAGDX11.90N/A
N/A
Transamerica Large Growth R6

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+2.54%
DNLI - ARWR
56%
Loosely correlated
+4.17%
NTLA - ARWR
54%
Loosely correlated
+1.11%
RGNX - ARWR
53%
Loosely correlated
+3.72%
BEAM - ARWR
52%
Loosely correlated
+1.51%
VERV - ARWR
50%
Loosely correlated
+5.67%
More

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+3.27%
VCYT - BCRX
46%
Loosely correlated
+2.15%
OCGN - BCRX
44%
Loosely correlated
+2.78%
ETNB - BCRX
38%
Loosely correlated
+4.23%
DNLI - BCRX
38%
Loosely correlated
+4.17%
ARWR - BCRX
38%
Loosely correlated
+2.54%
More